• Publications
  • Influence
Distinct mechanism for antidepressant activity by blockade of central substance P receptors.
The localization of substance P in brain regions that coordinate stress responses and receive convergent monoaminergic innervation suggested that substance P antagonists might have psychotherapeutic
Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
The observed improvements in ADAS-Cog and CIBIC+ following treatment with xanomeline provide the first evidence, from a large-scale, placebo-controlled clinical trial, that a direct-acting muscarinic receptor agonist can improve cognitive function in patients with AD.
A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, In the Absence and Presence of Metabolic Inhibition
The theoretical risk of cardiotoxicity associated with QTc prolongation should be balanced against the substantial clinical benefits associated with atypical antipsychotics and the likelihood of other toxicities.
Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.
Sertraline appears to be a safe and effective short-term treatment for children and adolescents with obsessive-compulsive disorder.
Positron emission tomography in Alzheimer's disease
PET is useful in quantifying regional cerebral dysfunction in DAT, even in the early stages of the disease, and reduces in ratio measures of relative metabolism in some parietal, temporal, and frontal regions were found.
Cholinesterase Inhibitors: A Therapeutic Strategy for Alzheimer Disease
Compared to placebo, new AChEIs in development provide modest improvements in cognition for patients with mild to moderate AD, with improved tolerability profiles and more convenient dosing relative to tacrine.
Relations between Neuropsychological and Cerebral Metabolic Asymmetries in Early Alzheimer's Disease
The results demonstrate that discrepancies between language and visuospatial deficits in patients with early AD are related to asymmetrical reductions in cerebral cortical glucose metabolism.
Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit
Cognitive improvement with rivastigmine in AD is associated with central inhibition of ChEs and support a role for central BuChE in addition to AChE inhibition in modulating cholinergic function in AD.
Review of the acetylcholinesterase inhibitor galanthamine
Evidence to date suggests galanthamine to be similar to other AChEIs in improving cognitive function in AD patients, which is well demonstrated by large-scale clinical trials.
Gender Differences in Depression and Antidepressant Pharmacokinetics and Adverse Events
Clinicians should be aware that potential differences in antidepressant pharmacokinetics may exist, and a dosage adjustment may be necessary for women to ensure a favorable drug response, compliance, and decreased incidence of adverse events.